US Stock Market Move | ZAI LAB (ZLAB.US) rose more than 5%, and Zoci is expected to become its first globally listed product in the oncology field.
On Wednesday, Zai Lab (ZLAB.US) rose more than 5%, to $19.72.
On Wednesday, ZAI LAB (ZLAB.US) rose more than 5%, closing at $19.72. In terms of news, on January 13, ZAI LAB introduced its 2026 strategic focus and clinical development progress at the 44th J.P. Morgan Healthcare Conference. Zocilurtatug pelitecan (Zoci) is expected to become the company's first globally marketed product in the field of oncology. The company plans to initiate three key registration studies by the end of 2026, including second-line and above small cell lung cancer, first-line small cell lung cancer, and neuroendocrine cancer.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
